ACCEL Lite: Selecting an Oral P2Y12 Inhibitor Post-MI: What’s the Best Choice?

Aug 23, 2022   |  Alison Bailey, MD, FACC; Spencer B. King III, MD, MACC; Matthew Aaron Cavender, MD, FACC; Francesco Franchi, MD

Podcast

Font Size
A
A
A

In this interview, Francesco Franchi, MD and Spencer B. King III, MD, MACC, with Matt A. Cavender MD, MPH, FACC, discuss how to make the best choice when selecting an oral P2Y12 inhibitor post-MI.




Clinical Topics: Heart Failure and Cardiomyopathies

Keywords: ACCELLite, Ticagrelor, Receptors, Purinergic P2Y12, Dual Anti-Platelet Therapy


< Back to Listings